Clinical trial
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
NCT03035188 is registered in ClinicalTrials.gov with SRH Wald-Klinikum Gera GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
- Lead sponsor
- SRH Wald-Klinikum Gera GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2017
- Completion date
- January 31, 2021
- Enrollment
- 40 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.